These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30425593)

  • 1. Impact of pegloticase on patient outcomes in refractory gout: current perspectives.
    Cunha RN; Aguiar R; Farinha F
    Open Access Rheumatol; 2018; 10():141-149. PubMed ID: 30425593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
    Schlesinger N; Lipsky PE
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical appraisal of the role of pegloticase in the management of gout.
    Ea HK; Richette P
    Open Access Rheumatol; 2012; 4():63-70. PubMed ID: 27790013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances in the treatment of gout: review of pegloticase.
    Reinders MK; Jansen TL
    Ther Clin Risk Manag; 2010 Oct; 6():543-50. PubMed ID: 21127695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study.
    Albert JA; Hosey T; LaMoreaux B
    Rheumatol Ther; 2020 Sep; 7(3):639-648. PubMed ID: 32720081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase.
    Lawrence Edwards N; Singh JA; Troum O; Yeo AE; Lipsky PE
    Rheumatology (Oxford); 2019 Mar; ():. PubMed ID: 30843588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
    Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
    Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegloticase Induced Hemolytic Anemia in a Patient With G6PD Deficiency.
    Adashek ML; Bourji KI
    J Hematol; 2018 May; 7(2):83-85. PubMed ID: 32300419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
    Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy.
    Zhang Z; Fu N; Li Q; Quan J
    Biochem Biophys Res Commun; 2023 Jul; 666():115-121. PubMed ID: 37182286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    Pillinger MH; Fields TR; Yeo AE; Lipsky PE
    J Rheumatol; 2020 Apr; 47(4):605-612. PubMed ID: 31203212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegloticase for chronic gout.
    Anderson A; Singh JA
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout.
    Broadwell A; Albert JA; Padnick-Silver L; LaMoreaux B
    Rheumatol Ther; 2022 Dec; 9(6):1549-1558. PubMed ID: 36136270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.